Calidi Biotherapeutics (CLDI) Assets (2021 - 2026)

Calidi Biotherapeutics has reported Assets for 6 years, with the latest figure at $7.2 million in Q2 2026.

• On a quarterly basis, Assets fell 22.96% year-over-year to $7.2 million in Q2 2026; TTM through Jun 2026 was $7.2 million, a 22.96% decrease from a year earlier, with the FY2025 full-year figure at $8.9 million, down 37.55% from the prior year.
• Assets was $7.2 million for Q2 2026 at Calidi Biotherapeutics, down from $8.9 million in the prior quarter.
• The five-year high for Assets was $231.2 million in Q1 2022, with the low at $20000.0 in Q2 2024.
• Average Assets over 5 years is $41.5 million, with a median of $14.0 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Assets sank 99.95% in 2024, then jumped 46655.0% in 2025.
• Over 5 years, Assets stood at $2.6 million in 2022, then surged by 285.79% to $10.0 million in 2023, then surged by 41.55% to $14.2 million in 2024, then tumbled by 37.55% to $8.9 million in 2025, then declined by 18.66% to $7.2 million in 2026.
• The last three Assets figures came in at $7.2 million (Q2 2026), $8.9 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.